Hudson Bay Capital Management’s Astria Therapeutics ATXS Stock Holding History

Hudson Bay Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-366,340	Closed	-$4.8M	–	1397
2025 Q4	$4.8M	Buy	+366,340	New	+$4.38M	0.02%	512

Hudson Bay Capital Management's ATXS Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 366,340 shares — an estimated $4.8M sold.

Hudson Bay Capital Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $4.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Hudson Bay Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 366,340 Astria Therapeutics shares in Q1 2026, an estimated $4.8M.
Hudson Bay Capital Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Hudson Bay Capital Management's Astria Therapeutics position peaked at $4.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.